With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs

Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news